Targeting leukemia stem cells in unfit acute myeloid leukemia with a CD70-directed third agent: promise and caveats from the ELEVATE trial. Comment on: “Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study”

Enriched recordOpen access

Tianxin Lyu

Abstract

Not available.

Authors

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

pubmed

Confidence 98%

europepmc

Confidence 96%

unpaywall

Confidence 95%

doaj

Confidence 92%

datacite

Confidence 0%

Referenced works

No local reference links have been materialized yet.

No local citing links have been materialized yet.

No reference metadata is available yet.

No additional external references are available.